Distribution of vitamin D receptor genes polymorphisms BsmI, and FokI in patients with multiple sclerosis in Serbian population

Lazar Bajić; Dejan Savić; Nikola Krstić; Ana Andrejević; Andrija Rančić; Miljana Mladenović; Tatjana Jevtović-Stoimenov

doi:10.5937/afmnai41-46218

Lazar Bajić University Clinical Center Niš, Clinic of Neurology, Niš, Republic of Serbia
Dejan Savić University Clinical Center Niš, Clinic of Neurology, Niš, Republic of Serbia
Nikola Krstić University of Niš, Faculty of Medicine, Niš, Republic of Serbia https://orcid.org/0000-0002-4398-1449
Ana Andrejević University of Niš, Faculty of Medicine, Niš, Republic of Serbia
Andrija Rančić University of Niš, Faculty of Medicine, Niš, Republic of Serbia https://orcid.org/0009-0007-6845-9458
Miljana Mladenović University of Niš, Faculty of Medicine, Niš, Republic of Serbia
Tatjana Jevtović-Stoimenov University of Niš, Faculty of Medicine, Department of Biochemistry, Niš, Republic of Serbia https://orcid.org/0000-0003-0600-5411

DOI: https://doi.org/10.5937/afmnai41-46218

Keywords: SNP, vitamin D receptor, vitamin D, neuroinflammatory diseases, multiple sclerosis

Abstract

Multiple sclerosis (MS) is chronic, autoimmune demyelinating disease of central nervous system. Connection between vitamin D deficiency, sun exposure and higher incidence of multiple sclerosis is long known, and number of subsequent studies have confirmed anti-inflammatory and neuroprotective properties of vitamin D. Vitamin D receptor (VDR) is responsible for most of the biological effects of the vitamin D, and the four VDR single nucleotide polymorphisms (SNPs) are identified as possible risk factors in several autoimmune diseases. The aim of our study was to determine relationship between susceptibility to MS and frequency of VDR polymorphisms BsmI (rs7975232) and FokI (rs2228570) in Serbian population. A total of 169 participants from southeastern Serbia were enrolled in our study, of whom 80 were diagnosed with multiple sclerosis. PCR-RFLP method was used for screening of FokI and BsmI VDR polymorphisms. There was a statistically significant difference in the distribution of FokI genotypes and alleles between the MS patients and control group (p = 0.006; p = 0.001). There was no statistically significant difference of BsmI genotypes and alleles between MS patients and healthy subjects (p = 0.140; p = 0.153). In conclusion, our case-control study showed that FokI rs228570 polymorphism is associated with risk of multiple sclerosis in Serbian population. In addition, we did not find correlation between the BsmI rs1544410 polymorphism and risk of multiple sclerosis in Serbian population.

Author Biographies

Dejan Savić, University Clinical Center Niš, Clinic of Neurology, Niš, Republic of Serbia

Assistant professor

Nikola Krstić, University of Niš, Faculty of Medicine, Niš, Republic of Serbia

Research assistant

Tatjana Jevtović-Stoimenov, University of Niš, Faculty of Medicine, Department of Biochemistry, Niš, Republic of Serbia

Full professor - University of Niš, Faculty of Medicine, Department of Biochemistry

References

1. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018; 31(6):752-9.

2. Savić D, Vojinović S, Lukić S, Savić Lj. Clinical and Neurophysiological Features in Patients Presenting Clinically Isolated Syndrome Suggestive on Multiple Sclerosis. Acta Facultatis Medicae Naissensis 2010; 27(2): 69-74.

3. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatr Scand Suppl 1960; 35(147):132-47.

4. Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the enviromental risk factors for multiple sclerosis? Brain 2010;133(Pt 7):1869-88.

5. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371(1-2): 1-12.

6. Wei R, Christakos S. Mechanisms underlying the regulation of innate and adaptive immunity by Vitamin D. Nutrients 2015; 7(10):8251-60.

7. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D₃ receptors in human Leukocytes. Science 1983; 221(4616):1181-3.

8. Peelen E, Knippenberg S, Muris AH, Thewissen M, Smolders J, Cohen Tervaert JW, et al. Effects of vitamin D on the peripheral adaptive immune system: A review. Autoimmun Rev 2011; 10(12):733-43.

9. Moosavi E, Rafiei A, Yazdani Y, Eslami M, Saeedi M. Association of serum levels and receptor genes BsmI, TaqI and FokI polymorphisms of vitamin D with the severity of multiple sclerosis. J Clin Neurosci 2021; 84: 75-81.

10. Bizzaro G, Antico A, Fortunato A, Bizzaro N. Vitamin D and Autoimmune Diseases: Is Vitamin D Receptor (VDR) Polymorphism the Culprit? Isr Med Assoc J 2017; 19(7):438-43.

11. Xiaoying C, Gooch H, Petty A, McGrath JJ, Eyles D. Vitamin D and the brain: Genomic and non-genomic actions. Mol Cell Endocrinol 2017; 453: 131-43.

12. Eyles DW, Almeras L, Benech P, Patatian A, Mackay-Sim A, McGrath J, et al. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol 2007; 103(3-5): 538-45.

13. Bivona G, Gambinoa CM, Iacolinoa G, Ciaccio V. Vitamin D and the nervous system. Neurol Res 2019; 41(9): 827-35.

14. Stumpf WE, Sar M, Clark SA. Brain Target Sites for 1,25-Dihydroxyvitamin D3. Science 1982; 215(4538):1403-5.

15. Eyles DW, Smith S, Kinobe R, Hewinson M, McGrath JJ. Distribution of the Vitamin D receptor and 1a-hydroxylase in human brain. J Chem Neuroanat 2005; 29(1): 21–30.

16. Murua SR, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu rev Pathol 2022; 17: 121-39.

17. Bivona G, Agnello L, Ciaccio M. The immunological implication of the new vitamin D metabolism. Cent Eur J Immunol 2018; 43(3): 331-4.

18. O’Gorman C, Lucas R, Taylor B. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 2012; 13: 11718-52.

19. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-hydroxyvitamin D levels in serum at he onset of multiple sclerosis. Mult Scler 2005; 11(3): 226-71.

20. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14(9): 1220-4.

21. Niino M, Fukuzawa T, Kikuchi S, Sasaki H. Therapeutic potential of vitamin D for multiple sclerosis. Curr Med Chem 2008; 15(5): 499-505.

22. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HTL, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cel Endocrinol 2001; 177(1): 145-56.

23. van Etten E, Verlinden L, Giulietti A, Ramos-Lopez E, Branisteanu DD, Ferreira GB, et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol 2007; 37(2): 359-405.

24. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D, et al. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res 1998; 13(11): 1691-9.

25. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284–7.

26. Durrin LK, Haile RW, Ingles SA, Coetzee GA. Vitamin D receptor 3'-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta 1999; 1453(3):311-20.

27. Agnello L, Scazzone C, Ragonese P, Salemi G, Lo Sasso B, Schillaci R, et al. Vitamin D receptor polymorphisms and 25-hydroxyvitamin D in a group of Sicilian multiple sclerosis patients. Neurol Sci 2016; 37(2): 261–7.

28. Sioka C, Papakonstantinou S, Markoula S, Gkartziou F, Georgiou A, Georgiou I, et al. Vitamin D receptor gene polymorphisms in multiple sclerosis patients in northwest Greece. J Negat Results Biomed 2011; 10:3.

29. Abdollahzadeh R, Fard MS, Rahmani F, Moloudi K, Kalani BS, Azarnezhad A. Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: a case-control study. J Neurol Sci 2016; 367: 148–51.

30. Al-Temaimi RA, Al-Enezi A, Al-Serri A, Alroughani R, Al-Mulla F. The association of vitamin D receptor polymorphisms with multiple sclerosis in a case-control study from Kuwait. PLoS One 2015; 10(11): e0142265.

31. Bermundez-Morales VH, Fierros G, Lopez RL, Martinez-Nava G, Flores-Aldana M, Flores-Rivera J, et al. Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults. J Neuroimmunol 2017; 306: 20-4.

32. Cierny D, Michalik J, Skerenova M, Kantorova E, Sivak Š, Javor J, et al. ApaI, BsmI and TaqI VDR gene polymorphisms in association with multiple sclerosis in Slovaks. Neurol Res 2016; 38(8): 678–84.

33. Krenek P, Benesova Y, Bienertova-Vasku J, Vasku A. The Impact of Five VDR polymorphisms on Multiple Sclerosis Risk and Progression: a Case-Control and Genotype-Phenotype Study. J Mol Neurosci 2018; 64(4): 559-66.

34. Kamisli O, Acar C, Sozen M, Tecellioglu M, Yücel FE, Vaizoglub D, et al. The Association between Vitamin D Receptor Polymorphisms and Multiple Sclerosis in a Turkish Population. Multi Scler Relat Disord 2018; 20: 78-81.

35. Garcia-Martin E, Agundez JAG, Martinez C, Benito-Leon J, Millan-Pascual J, Calleja P, et al. Vitamin D3 receptor (VDR) gene rs2228570 (Fok1) and rs731236 (Taq1) variants are not associated with the risk for multiple sclerosis: results of a new study and a meta-analysis. PLOS ONE 2013; 8(6): e65487.

36. Tizaoui K, Kaabachi W, Hamzaoui A, Hamzaoui K. Association between vitamin D receptor polymorphisms and multiple sclerosis: systematic review and meta-analysis of case-control studies. Cell Mol Immunol 2015; 12(2): 243-52.

37. Zhang D, Wang L, Zhang R, Li S. Association of vitamin D receptor gene polymorphisms and risk of multiple sclerosis: a meta analysis. Arch Med Res 2019; 50(6): 350-61.

38. Imani D, Razi B, Motallebnezhad M, Rezaei R. Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis. BMC Neurol 2019; 19(1): 339.